AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2300
-0.0300 (-2.38%)
As of 3:13PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.2600
Open1.2500
Bid1.23 x 1200
Ask1.25 x 900
Day's Range1.2100 - 1.2500
52 Week Range0.8200 - 2.0400
Volume68,890
Avg. Volume294,488
Market Cap21.963M
Beta (3Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE12 days ago

    Today’s Research Reports on Stocks to Watch: Arsanis and Aethlon Medical

    NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Biotech stocks Arsanis and Aethlon Medical were both seeing big gains on Tuesday on positive developments. Arsanis and privately held X4 Pharmaceuticals have agreed to merge and Aethlon announced it had received Breakthrough Device designation from FDA for their Hemopurifier in the treatment of cancer.

  • Zacks Small Cap Research13 days ago

    AEMD: Breakthrough Device Designation Granted for Cancer Therapy. Could Be Game-Changer for AEMD

    By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Breakthrough Device Designation Granted for Cancer Therapy This morning Aethlon (NASDAQ:AEMD) announced that they received Breakthrough ...

  • ACCESSWIRE13 days ago

    The Reason Healthcare Stocks Are Being Called Home By Investors

    CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector.

  • PR Newswire13 days ago

    Aethlon Medical's Cancer Therapy Receives "Breakthrough Device" Designation from the U.S. Food and Drug Administration

    SAN DIEGO, Nov. 27, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that it has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® for the treatment of cancer.  The Aethlon Hemopurifier is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses. FDA's Breakthrough Device program was established under the 21st Century Cures Act to facilitate more rapid patient access to breakthrough technologies with the potential to address life threatening disease conditions for which no approved or cleared treatment alternatives exist.

  • Zacks Small Cap Research28 days ago

    AEMD: Pivot Towards Cancer Makes Sense. FDA Filing For Breakthrough Device in Cancer

    Aethlon (AEMD) reported financial results for their fiscal second quarter ending September 30th and provided an operational update. As we had expected, no revenue was generated in the quarter – we do, however anticipate that revenue will return in fiscal Q3 and reflect initial progress under the recently awarded NCI grant evaluating Hemopurifier in the removal of breast cancer derived exosomes from the blood.

  • GlobeNewswire28 days ago

    Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswirelast month

    Aethlon Medical Announces Second Quarter Fiscal Year 2019 Results

    SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced results for its fiscal second quarter ...

  • PR Newswirelast month

    Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on November 6, 2018

    SAN DIEGO , Nov. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health today announced it will issue financial results for ...

  • PR Newswirelast month

    Aethlon Medical to Present at the NYC Oncology Conference

    Aethlon Medical is focused on addressing unmet needs in global health.  The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    Aethlon Medical to Present at the 2018 BIO Investor Forum

    SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the 2018 BIO Investor Forum on Thursday, October 18, 2018 at 3:15 p.m. Pacific Time.  The event is being held at the Westin St. Francis Hotel in San Francisco, California.  A live audio webcast of the presentation can be accessed at http://www.aethlonmedical.com/news-media/presentations.  A replay of the webcast will be available until January 15, 2019. Aethlon Medical is focused on addressing unmet needs in global health.  The Aethlon Hemopurifier® is clinical-stage immunotherapeutic device candidate to combat cancer and life-threatening viral infections. Aethlon Medical is also the majority owner of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

  • Simply Wall St.2 months ago

    How Financially Strong Is Aethlon Medical Inc (NASDAQ:AEMD)?

    While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of US$20m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • PR Newswire3 months ago

    Aethlon Medical Receives National Cancer Institute Award

    The Aethlon Hemopurifier is a first-in-class therapeutic technology designed for the rapid depletion of circulating viruses and cancer promoting exosomes. The FDA has designated the Hemopurifier as a "Breakthrough Device" for the treatment of life-threatening viruses for which there are no approved therapies.

  • Zacks Small Cap Research3 months ago

    AEMD: Compassionate Use, Real-World Data, Awaiting FDA Final Guidance

    Revenue of $150k represented the final payment from the phase I NCI cancer grant. A subsequent, phase 2 contract worth approximately $1.5M over two years, could follow – AEMD’s application for which is expected to be submitted later this year. Updates to several of the development programs were provided on the call, including that related to Hemopurifier under the Breakthrough Device designation, Hemopurifier’s potential role in cancer therapy and updates in the ESI segment – including CTE/TauSome study enrollment status and potential new opportunities.

  • PR Newswire4 months ago

    Aethlon Medical Announces First Quarter Fiscal Year 2019 Results

    SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • ACCESSWIRE4 months ago

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...

  • PR Newswire4 months ago

    Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018

    SAN DIEGO , Aug. 2, 2018  /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial ...

  • Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven
    Simply Wall St.5 months ago

    Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven

    Aethlon Medical Inc’s (NASDAQ:AEMD): Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. On 31 March 2018, theRead More...

  • PR Newswire6 months ago

    Guy Cipriani Joins Aethlon Medical's Board of Directors

    SAN DIEGO, June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the Nasdaq Rules. Mr. Cipriani is a business executive with nearly 20 years of experience in the pharmaceutical and biotech industries.

  • Zacks Small Cap Research6 months ago

    AEMD: AEMD In Active Discussions With FDA Regarding Hemopurifier Pathway

    Revenue of $75k, which was largely inline with our $89k estimate, relates entirely to a second milestone from the NCI cancer grant. Subsequent to the close of fiscal 2018, AEMD billed an additional $112k for work completed under this grant.

  • PR Newswire6 months ago

    Aethlon Medical Announces Fiscal 2018 Results

    SAN DIEGO , June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • PR Newswire6 months ago

    Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018

    Also Presenting at 2018 BIO International Convention on June 6, 2018 SAN DIEGO , May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs ...

  • Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?
    Simply Wall St.7 months ago

    Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?

    Aethlon Medical Inc (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$21.04M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...